CuraCell Oncology and One‑carbon Therapeutics were highlighted in Pharmaceutical Technology’s recent analysis of why Nordic biopharma innovation is outpacing commercial returns — and what that means for the region’s next generation of therapeutics.

The piece notes that while the Nordics continue to produce scientifically differentiated platforms, many emerging biotechs are struggling to secure the scale‑up capital required to translate that innovation into late‑stage development. Investors are increasingly selective, favouring companies with clear clinical rationale, strong translational data, and mechanisms capable of delivering meaningful patient impact.

Against this backdrop, CuraCell’s personalised TIL platform and One‑Carbon’s precision oncology approach exemplify the type of science‑driven, clinically anchored innovation still attracting attention. Both companies operate in areas where global demand for novel cancer therapies remains high, and where differentiated biology can help overcome the funding bottleneck facing the broader Nordic ecosystem.

The article frames the challenge as one of momentum: Nordic biotechs are generating world‑class ideas, but only those with robust clinical strategies and compelling value stories will break through the capital constraints shaping the region’s investment landscape.

Read the full article here.